Rexulti brexpiprazole

Weight gain is Rexulti's single biggest adherence threat: it appears in 21+ percent of Drugs.com side-effect mentions and triggers the dominant switching conversation, yet its rapid-onset mood lift in treatment-resistant MDD creates a vocal champion segment that no competitor currently matches.

• Rexulti's strongest asset is speed of perceived mood relief in treatment-resistant MDD patients, with multiple reviewers reporting meaningful change within days to two weeks, a rare differentiator worth amplifying in patient-facing education.
• Weight gain (21+ pct of side-effect mentions) is the top adherence killer: patients describe gaining 30 to 60 pounds and cite the resulting body-image distress as nearly re-triggering their depression, creating an urgent need for proactive metabolic counseling at initiation.
• Cost and access friction are the second structural barrier: patients report out-of-pocket sticker shock above $1,000 per month, prior-authorization delays, and confusion over savings-card eligibility, all of which interrupt the critical first-fill moment.
• Akathisia and insomnia drive the early-discontinuation cluster, but a meaningful subset frames mild restlessness as tolerable given the mood benefit, pointing to an opportunity for peer-to-peer normalization and dose-timing guidance from patient services.